Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Contraceptive vaginal ring

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    360 result(s) found for: Contraceptive vaginal ring. Displaying page 18 of 18.
    «« First « Previous 10  11  12  13  14  15  16  17  18 
    EudraCT Number: 2010-019690-15 Sponsor Protocol Number: GLP114179 Start Date*: 2010-07-27
    Sponsor Name:GlaxoSmithKline LLC
    Full Title: Estudio multicéntrico, aleatorizado, abierto y de grupos paralelos para determinar la eficacia y la seguridad de albiglutida en comparación con liraglutida en pacientes con diabetes mellitus de tip...
    Medical condition: Diabetes mellitus de tipo 2. Type 2 Diabetes Mellitus.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024435-16 Sponsor Protocol Number: HZC115247 Start Date*: 2011-05-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 12-week study to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on art...
    Medical condition: subjects with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002193-31 Sponsor Protocol Number: CRN00808-05 Start Date*: 2020-02-19
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRN00808 IN SUBJECTS WITH ACROMEGALY (ACROBAT ADVANCE)
    Medical condition: Acromegaly is typically caused by a growth hormone (GH) secreting tumor in the pituitary. Excess GH secretion results in excess secretion of insulin-like growth factor-1 (IGF-1) from the liver, whi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Completed) GR (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005245-37 Sponsor Protocol Number: M06-880 Start Date*: 2008-04-17
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012989-30 Sponsor Protocol Number: MS-LAQ-301E Start Date*: 2009-11-17
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral la...
    Medical condition: Laquinimod is developed for the treatment of relapsing remitting multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) FR (Completed) LT (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003387-43 Sponsor Protocol Number: GS-US-337-0102 Start Date*: 2013-01-31
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects ...
    Medical condition: Chronic Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003694-27 Sponsor Protocol Number: AC-055-303 Start Date*: 2011-11-17
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: SERAPHIN-OL: Study with an ERA in Pulmonary arterial Hypertension to Improve cliNical outcome (Open Label) Long-term single-arm open-label extension study of the SERAPHIN study, to assess the safe...
    Medical condition: symptomatic pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) FR (Completed) FI (Prematurely Ended) SE (Completed) AT (Completed) BE (Completed) DK (Completed) SK (Completed) PT (Prematurely Ended) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003272-12 Sponsor Protocol Number: 18-ICH-001 Start Date*: 2019-10-14
    Sponsor Name:Mayne Pharma LLC
    Full Title: A Phase 2 Randomized, Multi-center, Double-blind, Vehicle-controlled, 12-Week, Safety, Efficacy, and Systemic Exposure Study followed by a 12-Week Open-label Extension of Trifarotene (CD5789) Cream...
    Medical condition: Lamellar ichthyosis (LI) Autosomal Recessive Ichthyosis with Lamellar Scale
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10023686 Lamellar ichthyosis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020338-25 Sponsor Protocol Number: WA25046 Start Date*: 2010-11-02
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis
    Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) ES (Ongoing) BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) AT (Completed) FI (Completed) IT (Completed) GR (Completed) BG (Completed) DK (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000672-25 Sponsor Protocol Number: MK-5172-059 Start Date*: 2014-12-31
    Sponsor Name:Merck Sharp & Dohme Copr., a subsidary of Merck & Co.
    Full Title: A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis and Chi...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) EE (Completed) PL (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018419-14 Sponsor Protocol Number: CAMN107A2120 Start Date*: 2010-10-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ...
    Medical condition: pediatric patients with Gleevec® (imatinib)- resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009700 CML LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002586-39 Sponsor Protocol Number: MC-TER.2/SSc Start Date*: 2016-08-03
    Sponsor Name:medac GmbH
    Full Title: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapy in Subjects With Diffuse Cutaneous Systemic Sclerosis
    Medical condition: Diffuse cutaneous systemic sclerosis (dcSSc)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002830-38 Sponsor Protocol Number: M05-780 Start Date*: 2006-11-02
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
    Medical condition: Advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following one or more chemotherapy regimens.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-007107-32 Sponsor Protocol Number: M10-301 Start Date*: 2009-07-31
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-S...
    Medical condition: Non small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000484-28 Sponsor Protocol Number: LRS114688 Start Date*: 2011-08-15
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with f...
    Medical condition: Complicated Urinary tract infections (cUTI)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10046574 Urinary tract infection NOS LLT
    14.0 10021881 - Infections and infestations 10037606 Pyelonephritis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Prematurely Ended) HU (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005550-18 Sponsor Protocol Number: 1439A-024 Start Date*: 2015-08-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) DK (Completed) BE (Completed) IT (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000368-88 Sponsor Protocol Number: BEL114055 Start Date*: 2012-06-13
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta...
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) NL (Ongoing) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001718-41 Sponsor Protocol Number: 0517-31 Start Date*: 2012-09-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of...
    Medical condition: chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed) CZ (Completed) SE (Completed) HU (Completed) IT (Completed) PT (Completed) LV (Completed) PL (Completed) BG (Completed) GR (Completed) NO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002440-14 Sponsor Protocol Number: AC-055-302 Start Date*: 2008-05-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomati...
    Medical condition: To assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) FR (Completed) FI (Completed) SE (Completed) AT (Completed) DK (Completed) SK (Completed) PT (Prematurely Ended) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-020185-19 Sponsor Protocol Number: KP7242114 Start Date*: 2011-05-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Optimization of Treatment and Management of Schizophrenia in Europe
    Medical condition: Schizophrenia ICD-10 code F20 or schizophreniform disorder ICD-10 code F23.1
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10039647 Schizophreniform disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) DK (Prematurely Ended) AT (Completed) BE (Completed) IT (Completed) BG (Completed) RO (Suspended by CA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 10  11  12  13  14  15  16  17  18 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 09:01:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA